Nkar­ta un­der­scores safe­ty of CAR-NK, boasts ear­ly re­spons­es

The first gen­er­a­tion of per­son­al­ized CAR-T ther­a­pies made big waves in the treat­ment of lym­phoma for their stun­ning ef­fi­ca­cy. Nkar­ta is hop­ing its off-the-shelf nat­ur­al killer cell ap­proach will stand out on safe­ty — while keep­ing some of those im­pres­sive num­bers on re­spons­es.

In a new up­date from its Phase I dose es­ca­la­tion study, the South San Fran­cis­co-based biotech re­port­ed that sev­en out of 10 pa­tients treat­ed with the high­est dos­es of its NK cell ther­a­py, NKX019, achieved a com­plete re­sponse, trans­lat­ing to a com­plete re­sponse rate of 70%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER